In surprise decision, US approves muscular dystrophy drug - CNBC

1. In surprise decision, US approves muscular dystrophy drug  CNBC
2. Stocks To Watch With Stock Market At Record Highs Include Paycom Software  Investor's Business Daily
3. Sarepta’s surprise FDA approval for rare disease drug excites investors  MarketWatch
4. FDA OKs Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy  Medscape
5. Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug  CNA
6. View full coverage on Google News